Symbols / TRVN
TRVN Chart
About
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.50K |
| Enterprise Value | 24.11M | Income | -34.04M | Sales | 546.00K |
| Book/sh | -27.27 | Cash/sh | 15.59 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | 0.02 | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.76 | EV/Sales | 44.16 | Quick Ratio | 2.21 |
| Current Ratio | 2.42 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -48.89 | EPS next Y | -19.85 | EPS Growth | — |
| Revenue Growth | 57.20% | Earnings | 2024-11-07 07:00 | ROA | -62.39% |
| ROE | — | ROIC | — | Gross Margin | -190.48% |
| Oper. Margin | -19.71% | Profit Margin | 0.00% | Shs Outstand | 863.79K |
| Shs Float | 858.69K | Short Float | 7.03% | Short Ratio | 1.00 |
| Short Interest | — | 52W High | 1.80 | 52W Low | 0.00 |
| Beta | 0.61 | Avg Volume | 741.00 | Volume | 210.00 |
| Target Price | — | Recom | None | Prev Close | $0.01 |
| Price | $0.01 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-350.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-11-14 | down | HC Wainwright & Co. | Buy → Neutral | $5 |
| 2024-05-16 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-05-17 | reit | JMP Securities | Market Outperform → Market Outperform | $2 |
| 2023-03-31 | reit | JMP Securities | — → Market Outperform | $2 |
| 2023-03-31 | reit | HC Wainwright & Co. | — → Buy | $9 |
- TRVN - Trevena Inc Latest Stock News & Market Updates - Stock Titan hu, 27 Aug 2020 18
- Trevena’s High-Voltage Ride: Can Micro-Cap Volatility Turn Into Real Value? - AD HOC NEWS Wed, 11 Feb 2026 08
- Why Trevena (TRVN) Stock Is Down 43% Today - TradingView Mon, 07 Oct 2024 07
- Trevena Inc. (TRVN) Quarterly 10-Q Report - qz.com hu, 07 Nov 2024 08
- Trevena (TRVN) Stock Price, News & Analysis $TRVN - MarketBeat Mon, 13 Jul 2015 12
- Trevena to be delisted from Nasdaq over equity shortfall - Investing.com Fri, 04 Oct 2024 07
- A stock trader who's returned 2,700% since late-2020 details the chart pattern he uses to rapidly trade risky small caps - Business Insider Wed, 17 May 2023 07
- 3 Biotech Stocks Under $2 With Massive Upside Potential - Yahoo Finance Sun, 12 Apr 2020 07
- Trevena stock rises after opioid pain drug Olinvyk shows promise in trial - Seeking Alpha hu, 30 Mar 2023 07
- Trevena: Friday's Small-Cap Focus Stock - TheStreet Pro Wed, 13 Mar 2024 23
- ARMISTICE CAPITAL, LLC Acquires New Stake in Trevena Inc - GuruFocus Fri, 15 Nov 2024 08
- Trevena Stock Is a ‘Buy’ Ahead of Olinvyk Launch, Says Analyst - TipRanks hu, 05 Nov 2020 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 437.85K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -38.08M | -63.22M | -51.16M |
| TotalUnusualItems | 2.08M | 11.19M | 4.00K |
| TotalUnusualItemsExcludingGoodwill | 2.08M | 11.19M | 4.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -40.29M | -53.67M | -51.59M |
| ReconciledDepreciation | 334.00K | 382.00K | 428.00K |
| ReconciledCostOfRevenue | 1.67M | 3.02M | 954.00K |
| EBITDA | -35.99M | -52.03M | -51.16M |
| EBIT | -36.33M | -52.41M | -51.59M |
| NetInterestIncome | -2.25M | -805.00K | 161.00K |
| InterestExpense | 3.64M | 1.26M | 1.00K |
| InterestIncome | 1.40M | 451.00K | 162.00K |
| NormalizedIncome | -41.94M | -64.86M | -51.59M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -40.29M | -53.67M | -51.59M |
| TotalExpenses | 38.41M | 55.96M | 52.49M |
| TotalOperatingIncomeAsReported | -35.29M | -56.38M | -51.92M |
| DilutedAverageShares | 509.40K | 282.89K | 261.27K |
| BasicAverageShares | 509.40K | 282.89K | 261.27K |
| DilutedEPS | -79.00 | -189.75 | -200.00 |
| BasicEPS | -79.00 | -189.75 | -200.00 |
| DilutedNIAvailtoComStockholders | -40.29M | -53.67M | -51.59M |
| NetIncomeCommonStockholders | -40.29M | -53.67M | -51.59M |
| NetIncome | -40.29M | -53.67M | -51.59M |
| NetIncomeIncludingNoncontrollingInterests | -40.29M | -53.67M | -51.59M |
| NetIncomeContinuousOperations | -40.29M | -53.67M | -51.59M |
| TaxProvision | 318.00K | 0.00 | 0.00 |
| PretaxIncome | -39.97M | -53.67M | -51.59M |
| OtherIncomeExpense | -2.44M | 3.51M | 176.00K |
| OtherNonOperatingIncomeExpenses | -4.52M | -7.68M | 172.00K |
| GainOnSaleOfSecurity | 2.08M | 11.19M | 4.00K |
| NetNonOperatingInterestIncomeExpense | -2.25M | -805.00K | 161.00K |
| InterestExpenseNonOperating | 3.64M | 1.26M | 1.00K |
| InterestIncomeNonOperating | 1.40M | 451.00K | 162.00K |
| OperatingIncome | -35.29M | -56.38M | -51.92M |
| OperatingExpense | 36.74M | 52.94M | 51.54M |
| ResearchAndDevelopment | 16.33M | 18.21M | 13.43M |
| SellingGeneralAndAdministration | 20.41M | 34.73M | 38.11M |
| GeneralAndAdministrativeExpense | 38.11M | ||
| OtherGandA | 38.11M | ||
| GrossProfit | 1.46M | -3.44M | -387.00K |
| CostOfRevenue | 1.67M | 3.02M | 954.00K |
| TotalRevenue | 3.12M | -418.00K | 567.00K |
| OperatingRevenue | 3.12M | -418.00K | 567.00K |
| Line Item | 2023-12-31 | ||
|---|---|---|---|
| TreasurySharesNumber | 0.00 | ||
| OrdinarySharesNumber | 691.56K | 309.79K | 264.83K |
| ShareIssued | 691.56K | 309.79K | 264.83K |
| TotalDebt | 36.24M | 19.77M | 7.10M |
| TangibleBookValue | -7.66M | 15.60M | 64.63M |
| InvestedCapital | 23.15M | 29.03M | 64.63M |
| WorkingCapital | 27.65M | 32.28M | 61.54M |
| NetTangibleAssets | -7.66M | 15.60M | 64.63M |
| CapitalLeaseObligations | 5.44M | 6.33M | 7.10M |
| CommonStockEquity | -7.66M | 15.60M | 64.63M |
| TotalCapitalization | 23.15M | 29.03M | 64.63M |
| TotalEquityGrossMinorityInterest | -7.66M | 15.60M | 64.63M |
| StockholdersEquity | -7.66M | 15.60M | 64.63M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 1.00K | 0.00 |
| OtherEquityAdjustments | 1.00K | ||
| RetainedEarnings | -588.06M | -547.77M | -494.10M |
| AdditionalPaidInCapital | 580.39M | 563.36M | 558.72M |
| CapitalStock | 17.00K | 8.00K | 7.00K |
| CommonStock | 17.00K | 8.00K | 7.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 48.26M | 33.08M | 15.49M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 40.71M | 24.35M | 6.31M |
| DerivativeProductLiabilities | 5.47M | 5.48M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 35.23M | 18.87M | 6.31M |
| LongTermCapitalLeaseObligation | 4.42M | 5.44M | 6.31M |
| LongTermDebt | 30.81M | 13.43M | |
| CurrentLiabilities | 7.55M | 8.73M | 9.19M |
| CurrentDebtAndCapitalLeaseObligation | 1.01M | 899.00K | 792.00K |
| CurrentCapitalLeaseObligation | 1.01M | 899.00K | 792.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.09M | 1.97M | 2.13M |
| PayablesAndAccruedExpenses | 4.45M | 5.87M | 6.26M |
| CurrentAccruedExpenses | 2.15M | 3.50M | 1.72M |
| InterestPayable | 0.00 | 522.00K | 0.00 |
| Payables | 2.30M | 2.37M | 4.55M |
| AccountsPayable | 2.30M | 2.37M | 4.55M |
| TotalAssets | 40.60M | 48.68M | 80.12M |
| TotalNonCurrentAssets | 5.40M | 7.67M | 9.40M |
| OtherNonCurrentAssets | 540.00K | 1.96M | 2.85M |
| NetPPE | 4.86M | 5.71M | 6.55M |
| AccumulatedDepreciation | -2.60M | -2.76M | -2.49M |
| GrossPPE | 7.46M | 8.47M | 9.04M |
| Leases | 3.08M | 3.08M | 3.08M |
| OtherProperties | 3.70M | 4.26M | 4.76M |
| MachineryFurnitureEquipment | 673.00K | 1.13M | 1.20M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 35.20M | 41.01M | 70.72M |
| OtherCurrentAssets | 2.23M | 1.78M | 1.45M |
| PrepaidAssets | 1.45M | ||
| Inventory | 0.00 | 906.00K | 2.35M |
| FinishedGoods | 0.00 | 906.00K | 2.35M |
| Receivables | 0.00 | ||
| AccountsReceivable | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 32.98M | 38.32M | 66.92M |
| CashAndCashEquivalents | 32.98M | 38.32M | 66.92M |
| CashEquivalents | 29.82M | 28.67M | 58.77M |
| CashFinancial | 3.16M | 9.65M | 8.15M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -33.08M | -51.51M | -50.21M |
| RepaymentOfDebt | -12.00K | -8.00K | -8.00K |
| IssuanceOfDebt | 14.78M | 13.91M | 0.00 |
| IssuanceOfCapitalStock | 9.49M | 9.64M | 7.95M |
| CapitalExpenditure | -41.00K | -28.00K | -16.00K |
| InterestPaidSupplementalData | 801.00K | 604.00K | 0.00 |
| EndCashPosition | 33.52M | 40.28M | 68.23M |
| BeginningCashPosition | 40.28M | 68.23M | 110.71M |
| ChangesInCash | -6.76M | -27.95M | -42.48M |
| FinancingCashFlow | 26.31M | 23.50M | 7.73M |
| CashFlowFromContinuingFinancingActivities | 26.31M | 23.50M | 7.73M |
| NetOtherFinancingCharges | -2.00K | -37.00K | -393.00K |
| ProceedsFromStockOptionExercised | 2.06M | 0.00 | 187.00K |
| NetPreferredStockIssuance | 0.00 | 1.65M | 0.00 |
| PreferredStockIssuance | 0.00 | 1.65M | 0.00 |
| NetCommonStockIssuance | 9.49M | 8.00M | 7.95M |
| CommonStockIssuance | 9.49M | 8.00M | 7.95M |
| NetIssuancePaymentsOfDebt | 14.76M | 13.90M | -8.00K |
| NetLongTermDebtIssuance | 14.76M | 13.90M | -8.00K |
| LongTermDebtPayments | -12.00K | -8.00K | -8.00K |
| LongTermDebtIssuance | 14.78M | 13.91M | 0.00 |
| InvestingCashFlow | -41.00K | 18.00K | -16.00K |
| CashFlowFromContinuingInvestingActivities | -41.00K | 18.00K | -16.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 46.00K | 0.00 |
| SaleOfInvestment | 0.00 | 33.00M | 0.00 |
| PurchaseOfInvestment | 0.00 | -32.95M | 0.00 |
| NetPPEPurchaseAndSale | -41.00K | -28.00K | -16.00K |
| PurchaseOfPPE | -41.00K | -28.00K | -16.00K |
| OperatingCashFlow | -33.03M | -51.48M | -50.20M |
| CashFlowFromContinuingOperatingActivities | -33.03M | -51.48M | -50.20M |
| ChangeInWorkingCapital | -1.75M | -849.00K | -3.85M |
| ChangeInOtherCurrentLiabilities | -887.00K | -758.00K | -9.70M |
| ChangeInOtherCurrentAssets | 0.00 | 9.00M | |
| ChangeInPayablesAndAccruedExpense | -1.40M | -676.00K | 1.53M |
| ChangeInPrepaidAssets | 1.21M | -2.34M | |
| ChangeInInventory | 10.00K | -624.00K | -2.35M |
| ChangeInReceivables | 522.00K | 1.21M | -2.34M |
| ChangesInAccountReceivables | 522.00K | 1.21M | -2.34M |
| OtherNonCashItems | 3.20M | 3.06M | 413.00K |
| StockBasedCompensation | 2.93M | 3.68M | 4.41M |
| AmortizationOfSecurities | 0.00 | -46.00K | 0.00 |
| DepreciationAmortizationDepletion | 334.00K | 382.00K | 428.00K |
| DepreciationAndAmortization | 334.00K | 382.00K | 428.00K |
| Depreciation | 334.00K | 382.00K | 428.00K |
| OperatingGainsLosses | 2.55M | -4.03M | -6.00K |
| GainLossOnInvestmentSecurities | 2.55M | -4.03M | -6.00K |
| NetIncomeFromContinuingOperations | -40.29M | -53.67M | -51.59M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for TRVN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|